T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$3.3B |
| 2 |
Eli Lilly
LLY
|
+$2.75B |
| 3 |
AstraZeneca
AZN
|
+$1.98B |
| 4 |
Coupang
CPNG
|
+$1.54B |
| 5 |
Fortinet
FTNT
|
+$1.48B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NXP Semiconductors
NXPI
|
+$2.34B |
| 2 |
Morgan Stanley
MS
|
+$2.26B |
| 3 |
Airbnb
ABNB
|
+$2.04B |
| 4 |
Qualcomm
QCOM
|
+$1.95B |
| 5 |
NVIDIA
NVDA
|
+$1.81B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.35% |
| 2 | Healthcare | 16.19% |
| 3 | Consumer Discretionary | 15.55% |
| 4 | Financials | 12.84% |
| 5 | Communication Services | 12.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
XLRN
276
DELISTED
Acceleron Pharma
XLRN
| $727M | 0.07% |
5,358,304
+48,538
| +0.9% | +$6.27M |
|
277
Analog Devices
ADI
$187B
| $720M | 0.07% |
4,642,427
+296,759
| +7% | +$45.6M |
|
278
Broadridge
BR
$19.3B
| $719M | 0.07% |
4,698,878
+206,414
| +5% | +$30.5M |
|
279
Verizon
VZ
$195B
| $718M | 0.07% |
12,351,899
-4,006,864
| -24% | -$226M |
|
280
Pinduoduo
PDD
$127B
| $717M | 0.07% |
5,352,943
+1,446,170
| +37% | +$244M |
|
|
SEM
281
DELISTED
Select Medical
SEM
| $714M | 0.07% |
38,857,190
-2,158,136
| -5% | -$35.4M |
|
282
Amgen
AMGN
$225B
| $711M | 0.07% |
2,856,339
-204,010
| -7% | -$48.7M |
|
283
DuPont de Nemours
DD
$19.5B
| $695M | 0.07% |
7,166,991
-14,067,839
| -66% | -$1.35B |
|
284
Descartes Systems
DSGX
$6.65B
| $689M | 0.07% |
11,317,023
-236,176
| -2% | -$14.4M |
|
285
Revvity
RVTY
$13.2B
| $682M | 0.07% |
5,312,457
+1,992,799
| +60% | +$276M |
|
286
Franco-Nevada
FNV
$45.5B
| $677M | 0.07% |
5,401,881
+926,261
| +21% | +$112M |
|
287
Intel
INTC
$509B
| $664M | 0.07% |
10,375,146
+2,692,523
| +35% | +$160M |
|
288
Toro Company
TTC
$9.32B
| $662M | 0.07% |
6,422,441
+1,884,325
| +42% | +$188M |
|
289
BWX Technologies
BWXT
$15.8B
| $662M | 0.07% |
10,040,345
-228,134
| -2% | -$13.7M |
|
290
Rayonier
RYN
$6.47B
| $656M | 0.07% |
22,435,988
-886,636
| -4% | -$26.1M |
|
291
Costco
COST
$421B
| $656M | 0.07% |
1,861,666
-347,916
| -16% | -$121M |
|
|
NVRO
292
DELISTED
NEVRO CORP.
NVRO
| $655M | 0.07% |
4,694,704
+666,384
| +17% | +$109M |
|
293
Ascendis Pharma A/S
ASND
$16.8B
| $654M | 0.07% |
5,073,336
-1,545,706
| -23% | -$235M |
|
294
TC Energy
TRP
$66.3B
| $652M | 0.07% |
14,255,241
-1,566,111
| -10% | -$69.5M |
|
295
Kimberly-Clark
KMB
$36.2B
| $650M | 0.07% |
4,674,541
+283,040
| +6% | +$37.6M |
|
296
Webster Financial
WBS
$12.8B
| $628M | 0.06% |
11,400,820
-1,192,994
| -9% | -$63.5M |
|
297
RPM International
RPM
$14.7B
| $627M | 0.06% |
6,822,629
+70,676
| +1% | +$6.11M |
|
298
CME Group
CME
$94.3B
| $625M | 0.06% |
3,058,118
-1,681,202
| -35% | -$331M |
|
299
Idexx Laboratories
IDXX
$45B
| $624M | 0.06% |
1,274,533
-737,860
| -37% | -$370M |
|
300
Expedia Group
EXPE
$39.1B
| $619M | 0.06% |
3,597,728
+3,357,964
| +1,401% | +$517M |
|
Similar funds
T. Rowe Price Associates's Q1 2021 Portfolio in Review
As of Q1 2021, T. Rowe Price Associates held 2,908 positions worth $999B, up 2.5% from $974B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
T. Rowe Price Associates's Q1 2021 filing shows 248 new, 1,171 increased, 1,334 reduced and 66 closed positions. Its largest new stake was Coupang: 33,380,859 shares worth $1.63B. The largest sale was NXP Semiconductors, an estimated $2.34B.
By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q1 2021 buy was Coupang: 33,380,859 shares worth $1.63B.
- T. Rowe Price Associates added most to Zoom in Q1 2021, an estimated $3.3B increase.
- T. Rowe Price Associates's biggest Q1 2021 reduction was NXP Semiconductors, cutting an estimated $2.34B.
- T. Rowe Price Associates fully exited CONCHO RESOURCES INC. in Q1 2021, selling an estimated $205M.
- T. Rowe Price Associates's ten largest holdings make up 24% of its $999B portfolio in Q1 2021.
- T. Rowe Price Associates opened 248 new positions and closed 66 in Q1 2021.
- T. Rowe Price Associates's portfolio value rose 2.5% quarter-over-quarter to $999B.
Based on T. Rowe Price Associates's 13F filing for Q1 2021, filed 17 May 2021.